Tertiary lymphoid structures (TLSs)—organized clusters of immune cells within tumors—are critical for effective cancer immunotherapy, according to a study published in Science. Researchers at the Icahn School of Medicine at Mount Sinai identified type 1 conventional dendritic cells (cDC1s) as the essential architects that form and maintain these structures, suggesting a new path for improving … Read more
A multidisciplinary panel of 60 specialists has released the 2025 edition of the Chinese consensus on the diagnosis and treatment of prolactinomas, published in the Chinese Neurosurgical Journal on June 8, 2026. This evidence-based framework standardizes care across endocrinology, neurosurgery, and radiology to improve early detection and patient outcomes for the most common hormone-secreting pituitary … Read more
Robot-assisted stereotactic surgery successfully drained six deep-seated intracranial abscesses in a 21-year-old patient during a single minimally invasive procedure, according to a case report published in the Chinese Neurosurgical Journal. Led by Professor Jun Wang of the First Hospital of China Medical University, the surgical team used preoperative MRI and intraoperative CT fusion to navigate … Read more
New deep learning frameworks for brain tumor detection are increasingly utilizing stratified patient-wise cross-validation and quantitative explainability (XAI) metrics to bridge the gap between algorithmic performance and clinical reliability. By integrating architectures like InceptionV3 with rigorous testing on independent datasets, researchers are addressing critical hurdles in medical AI, specifically data scarcity and the “black box” … Read more
A blood test detecting circulating tumour DNA (ctDNA) after surgery can identify colorectal cancer patients most likely to benefit from adjuvant chemotherapy, according to research presented at the 2026 ESMO Gastrointestinal Cancers Congress. The Phase II GALAXY study, led by researchers from Hyogo Medical University and collaborators including the University of Oxford, found that patients … Read more
The U.S. Food and Drug Administration approved zenocutuzumab as a second-line therapy for NRG1-positive cholangiocarcinoma on May 8. According to results from the eNRGy phase 2 clinical trial published in the Journal of Clinical Oncology, the drug more than doubled the median progression-free survival to 9.2 months, compared to the approximately four months typically seen … Read more
Revolution Medicines will present clinical data on its RAS(ON) inhibitor pipeline at the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Munich, Germany, from July 1–4, 2026. The company intends to showcase four presentations covering Phase 1/2 and Phase 3 trials for targeted therapies addressing RAS-addicted cancers, including pancreatic ductal adenocarcinoma (PDAC). … Read more
Researchers at the RCSI University of Medicine and Health Sciences have developed a novel mRNA vaccine for neuroblastoma using self-assembling peptide nanoparticles. According to study lead Olga Piskareva, the vaccine, which targets the glypican 2 (GPC2) antigen, reduced tumor volume by 70% in murine models. This approach offers a potential alternative to traditional lipid-based delivery … Read more
Researchers at the Rutgers Cancer Institute have successfully reduced patient wait times for complex cancer care by utilizing “digital twin” simulations to re-engineer clinic workflows. According to a study published in the Annals of Operations Research, this data-driven approach allowed the clinic to increase daily infusion capacity from 50 to 80 patients while slashing blood … Read more
Myriad Genetics has expanded the availability of its Precise MRD™ test to patients with breast, colorectal, and renal cancers, providing an ultrasensitive method for tracking circulating tumor DNA (ctDNA). According to the June 23, 2026, company announcement, the test uses whole-genome sequencing to monitor disease status across the cancer care continuum, potentially impacting the treatment … Read more